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Elevating Akt activation is an obvious clinical strategy to prevent
progressive neuronal death in neurological diseases. However,
this endeavor has been hindered because of the lack of speciﬁc
Akt activators. Here, from a cell-based high-throughput chemical
genetic screening, we identiﬁed a small molecule SC79 that
inhibits Akt membrane translocation, but paradoxically activates
Akt in the cytosol. SC79 speciﬁcally binds to the PH domain of Akt.
SC79-bound Akt adopts a conformation favorable for phosphory-
lation by upstream protein kinases. In a hippocampal neuronal
culture system and a mouse model for ischemic stroke, the
cytosolic activation of Akt by SC79 is sufﬁcient to recapitulate
the primary cellular function of Akt signaling, resulting in aug-
mented neuronal survival. Thus, SC79 is a unique speciﬁc Akt
activator that may be used to enhance Akt activity in various
physiological and pathological conditions.
drug discovery | cell signaling
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kt/PKB, a serine/threonine protein kinase with antiapoptotic
activity, is one of the major downstream targets of PtdIns
(3,4,5)P3 signaling pathway. It contains a pleckstrin homology
domain (PH domain) that speciﬁcally binds PtdIns(3,4,5)P3 on
the plasma membrane. Under physiological condition, the PtdIns
(3,4,5)P3-mediated membrane translocation of Akt is essential
for its phosphorylation at Thr308 and Ser473 and the subsequent
activation. Activated Akt, in turn, phosphorylates a variety of
proteins, including several associated with cell survival/death
pathways such as BAD and FoxOs (1, 2). Akt is a crucial me-
diator of cell survival and its deactivation is implicated in various
stress-induced pathological cell death and degenerative diseases.
For example, Akt was shown to be important in mediating the
survival of a range of neuronal cell types. Deactivation of Akt
was implicated in pathogenesis of numerous neurological dis-
eases (3–7). In addition, Akt signaling is critically important for
myelination of axons (8, 9). Activation of Akt in myelin-forming
cells will be beneﬁcial for various neuropathies, such as multiple
sclerosis, caused by demyelination of axons. The acute activation
of Akt is also beneﬁcial to prevent apoptosis of cardiomyocytes
upon ischemic injury (6).
Elevating Akt signaling can be achieved by activating upstream
components by using certain growth factors or growth factor
receptor agonists. Akt phosphorylation and activation are di-
rectly determined by the level of PtdIns(3,4,5)P3 on the plasma
membrane, which is regulated by phosphatidylinositol 3′-kinases
(PI3-kinase or PI3K), the tumor suppressor PTEN, SHIP, and
5ptase IV (a phosphoinositide-speciﬁc inositol polyphosphate
5-phosphatase IV). It was reported that two inositol phosphates,
InsP7 and Ins(1,3,4,5)P4, compete for Akt-PH domain binding
with PtdIns(3,4,5)P3 both in vitro and in vivo, providing another
level of regulation for Akt membrane translocation and activa-
tion (10–13). Thus, activation of Akt can also be achieved by
manipulating these related cellular factors. However, none of
theseapproaches are speciﬁc because multiple signaling pathways
are activated downstream of the receptors or PtdIns(3,4,5)P3.
Despite the great need of Akt activator for a variety of thera-
peutic applications, the effort of identifying genuine activator of
Aktwasultimatelyunsuccessful.Inthisstudy,wesetupacell-based
high-throughput chemical genetic screening system aiming to
identifying novel Akt inhibitors that speciﬁcally target PtdIns
(3,4,5)P3-mediated Akt membrane translocation. However, par-
adoxically, from this screening, we discovered a genuine activator
of Akt that suppressed PHAKT-GFP plasma membrane trans-
location but enhanced Akt phosphorylation. It enables cytosolic
activation of Akt independent of PtdIns(3,4,5)P3-mediated Akt
membrane translocation. In addition, this activator-induced Akt
activation recapitulates the primary function of Akt signaling be-
causeitefﬁcientlypreventedexcitotoxicity-inducedneuronaldeath.
Results
High-Throughput Screening for Inhibitors of Akt Plasma Membrane
Translocation. To visualize Akt translocation, we used the PH
domain of Akt (PHAkt) fused with green ﬂuorescent protein
(PHAkt-GFP) as a marker. When serum-starved cells were
stimulated with insulin-like growth factor (IGF), the membrane
translocation of PHAkt-GFP occurred within 5 min. As a con-
trol, IGF-elicited membrane translocation was signiﬁcantly sup-
pressed in cells treated with LY294002, which inhibits PI3K
activity and, therefore, reduces the level of PtdIns(3,4,5)P3
on the plasma membrane (SI Appendix, Fig. S1). Using a stable
HeLa cell line expressing PHAkt-GFP fusion protein (SI Appen-
dix, Fig. S2), we performed a cell-based chemical genetic
screening for compounds that suppress IGF-induced PHAkt-GFP
membrane translocation (SI Appendix, Fig. S3). The pilot
screening identiﬁed 21 positive hits from a library containing 480
bioactive compounds. Several chemicals known to be able to in-
hibit PtdIns(3,4,5)P3 signaling, including Wortmannin, Celastrol,
Quercetin, and LY294002, were among the identiﬁed compounds
(SI Appendix, Fig. S4 and Table S1). The subsequent high-
throughput screening (HTS) of more than 60,000 synthetic
chemical compounds (SI Appendix, Table S2) identiﬁed 125 pos-
itive hits (Fig. 1A and SI Appendix, Table S3 and Fig. S5).
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on PHAkt-GFP membrane translocation, we examined PH-Akt
translocation by using time-lapse ﬂuorescent imaging. We found
that 25 of the positive compounds generated autoﬂuorescence
and their effect on PH-Akt membrane translocation was, in fact,
the result of greatly enhanced background ﬂuorescence (SI Ap-
pendix, Table S3). Fifty-four of the initial 125 positive compounds
could inhibit IGF-induced Akt membrane translocation at the
concentration of 8 μg/mL (SI Appendix, Figs. S6 and S7). How-
ever, these compounds may have a general translocation in-
hibitory effect and, thus, prevent any protein from translocating
to the plasma membrane. In addition, some “positive hits” may
affect PtdIns(3,4,5)P3 level via modulating cellular levels of
phosphoinositides. To eliminate these possibilities, we examined
PtdIns(4,5)P2-mediated protein translocation. We used a cell
line stably expressing GFP-PLC-delta1-PH domain, which spe-
ciﬁcally binds to PtdIns(4,5)P2, but not PtdIns(3,4,5)P3 (14, 15).
It appeared that none of the positive hit compounds suppressed
the membrane localization of GFP-PLC-delta1-PH (SI Appendix,
Fig. S8). Another general issue in cell-based HTS is the indirect
effects of compounds on the assay readout (e.g., via inducing cell
death or affecting transcription or translation). None of the
positive hit compounds caused morphological changes in this
short period, suggesting that the inhibited PHAKT-GFP plasma
membrane translocation was not the result of cell death (SI Ap-
pendix, Fig. S9). However, many positive compounds turned out
to be toxic when cells were incubated with them for longer time
(SI Appendix, Fig. S9 and Table S4), indicating that these chem-
icals may target cellular components other than Akt.
Synthetic Compound SC79 Suppresses PHAKT-GFP Plasma Membrane
Translocation but Enhances Akt Phosphorylation and Activation in
the Cytosol. To investigate the effect of each positive hit com-
pound on Akt activity, we next assessed IGF-elicited Akt
phosphorylation, a commonly used reporter for Akt activation.
To our surprise, we unexpectedly found that one of the positive
hits, SC79, could suppress PHAKT-GFP plasma membrane
translocation but enhance Akt phosphorylation (Fig. 1B). Upon
PtdIns(3,4,5)P3-mediated recruitment to the plasma membrane,
Akt is phosphorylated at two different regulatory sites, T308 and
S473, respectively. Both phosphorylations were augmented by
SC79 treatment (Fig. 1C). In addition, SC79 not only enhanced
IGF1-induced Akt phosphorylation in serum-starved cells, but
also elevated the level of Akt phosphorylation in cells grown in
serum-rich medium (Fig. 1D). The kinetic studies revealed that
Akt phosphorylation could be increased within a minute of SC79
treatment (SI Appendix, Fig. S10).
Various chemicals targeting the ATP binding pocket of Akt
and inhibiting its kinase activity paradoxically lead to hyper-
phosphorylation of Akt (16, 17) (SI Appendix,F i g .S 1 1 ). Im-
portantly, once the drug is removed, such phosphorylated Akt
was shown to be fully active (18). One explanation for SC79-
induced Akt phosphorylation might be that SC79 transiently
binds to the ATP binding pocket, leading to Akt phosphoryla-
tion, and then readily dissociates from the activated Akt. To
rule out this possibility, we ﬁrst determined whether SC79 could
i n h i b i tt h eA k tk i n a s ea c t i v i t yi n intact cells. At a comparable
concentration,SC79failedtodemonstrateanyinhibitiontoward
Akt kinase activity. Instead, phosphorylation of several down-
stream effectors of Akt, including and FOXO, was much en-
hanced in SC79-treated cells, suggesting that SC79-induced
augmentation of Akt phosphorylation led to enhanced Akt ki-
nase activity (Fig. 1D). A compound that shares structure simi-
larity with SC79, HA14-1, showed the same effect (SI Appendix,
Fig. S11).
SC79 enhanced Akt phosphorylation but inhibited PtdIns
(3,4,5)P3-mediated Akt membrane translocation, indicating that
the binding between Akt and PtdIns(3,4,5)P3 may not be
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Fig. 1. High-throughput screening identiﬁes a synthetic compound SC79 that suppresses PHAKT-GFP plasma membrane translocation but enhances Akt
phosphorylation and activation in the cytosol. (A) High-throughput screening identiﬁed SC79 as an inhibitor of Akt-PH domain translocation and an enhancer
of Akt phosphorylation. (B) Chemical structure of SC79. (C) SC79 augmented Akt phosphorylation at both the Thr308 and S473 sites. (D) SC79 enhanced
Akt phosphorylation and its kinase activity. Phosphorylation of downstream targets, GSK-3β and Foxo, was detected by using speciﬁc Phospho-GSK3β and
Phospho-Foxo antibodies. (E) The representative images of SC79-induced cytosolic phosphorylation of Akt. Cells were serum-starved for overnight and
then treated with IGF or SC79 for 15 min. The ﬁxed cells were immunostained with the phospho-Akt (S473) antibody. (F) SC79-induced cytosolic phos-
phorylation of Akt analyzed by Western blotting. HeLa cells were serum starved for 1 h and treated with IGF (100 ng/mL) or SC79 (4 μg/mL) for 30 min. Total
cell lysate, cytosolic, and membrane fractions were resolved by SDS/PAGE and analyzed for phospho-Akt (S473), Total Akt, Tubulin (cytosolic marker),
and Orai1 (membrane marker) by Western blotting. (G) SC79 treatment led to phosphorylation of Akt (K14R) mutant, a PH domain mutant incapable of
binding to PtdIns(3,4,5)P3. Serum-starved cells stably expressing the V5-tagged Akt (K14R) were treated with IGF, SC79, or in combination before analysis
for Akt phosphorylation. The phosphorylated forms of endogenous and mutant Akt (K14R) were indicated by arrows. A mouse monoclonal V5 antibody
was used to detect Akt (K14R) mutant and to serve as the loading control. (H) Pretreatment with PI3K inhibitor wortmannin abolished SC79-induced Akt
activation.
10582 | www.pnas.org/cgi/doi/10.1073/pnas.1202810109 Jo et al.essential for SC79-induced Akt hyperactivation. Supporting this
notion, both immunostaining and biochemical analyses indicate
that IGF-induced Akt phosphorylation occurred near the plasma
membrane where the PtdIns(3,4,5)P3 was generated, whereas
SC79-induced Akt phosphorylation mainly occurred in the cy-
tosol (Fig. 1 E and F). In addition, SC79 also enhanced the
phosphorylation of an Akt mutant (K14R) that is deﬁcient in
PtdIns(3,4,5)P3 binding function and, thus, cannot be activated
by IGF (Fig. 1G). Nevertheless, it is noteworthy that even in the
presence of SC79, Akt phosphorylation relied on production of
a certain amount of PtdIns(3,4,5)P3, because PDK1 still required
PtdIns(3,4,5)P3 for activation. Therefore, treatment with PI3K
inhibitor wortmannin signiﬁcantly suppressed Akt phosphoryla-
tion in both SC79-treated and -untreated cells (Fig. 1H).
SC79 Enhances Phosphorylation of all Three Akt Isoforms and Elevates
Akt Activation in Multiple Cell Types. There are three Akt isoforms
in mammalian cells with an almost identical PtdIns(3,4,5)P3-
binding PH domain. The original screening was conducted by
using Akt1-PH domain. In some contexts, the differential acti-
vation and functional speciﬁcity of Akt isoforms have been ob-
served. For instance, in neutrophils, Akt2 but not Akt1 was
shown to be recruited to the plasma membrane upon chemo-
attractant stimulation (19). We, therefore, wondered whether
SC79 could show any isoform speciﬁc activity. We tested this
possibility in cells stably expressing individual Akt isoform. SC79
was able to potently activate all isoforms, indicating that it may
act as a pan-Akt activator (Fig. 2A). In addition, the effect of
SC79 on Akt activation was not limited to HeLa cells. SC79-
induced Akt hyperphosphorylation was detected in all cell types
examined in this study, including HEK293, HeLa, HL60, NB4,
and HsSulton (B cells) cells (Fig. 2B).
SC79 Speciﬁcally Enhances Akt Phosphorylation and Activation in
both Receptor Tyrosine Kinase- and GPCR-Mediated Signaling. It is
known that PH-domain membrane translocation can also be in-
duced by activation of G protein coupled receptors (GPCRs) (8,
11). The general Akt activator should also enhance GPCR-medi-
ated Akt activation. To test this hypothesis, we examined the effect
of SC79 on Akt phosphorylation in neutrophil-like differentiated
HL60 cells (dHL60). Chemoattractants, such as methionyl-leucyl-
phenylalanine (fMLP), bind receptors on cell membrane, leading
to activation of GPCR and PtdIns(3,4,5)P3/Akt signaling. Treat-
ment with SC79-elevated Akt phosphorylation in both unstimu-
lated- and fMLP-stimulated dHL60 cells, demonstrating that SC79
also acts as an Akt activator in GPCR signaling (Fig. 2C). Similar
to what was observed in HeLa cells, SC79-elicited Akt activation in
dHL60 cells also mainly occurred in cytosol (Fig. 2D).
Effect of SC79 on Akt appeared to be speciﬁc. A recent sys-
tematic study revealed a great diversity among various PtdIns
(3,4,5)P3-binding PH domains (20). For example, the PH do-
main of IL2-inducible T-cell Kinase (ITK), a Tec family protein
tyrosine kinase, is diverged from that of Akt (SI Appendix, Fig.
S12). Although both Akt and ITK were translocated to the
plasma membrane upon IGF stimulation, pretreatment with
SC79 signiﬁcantly inhibited Akt-PH domain translocation, but
not Itk-PH domain translocation, even at a higher concentration
(Fig. 2E). We also carried out a converse experiment in which
cells were prestimulated with IGF followed by SC79 treatment.
Consistent with its inhibition of membrane translocation, SC79
led to an efﬁcient dissociation of Akt-PH domain from the
membrane while it showed a relative inefﬁcacy toward Itk PH
domain (Fig. 2F).
SC79 Directly Binds to Akt and Converts It to an Active Conformation
More Amenable to Be Phosphorylated by Upstream Kinases. We
hypothesize that SC79 directly binds to Akt-PH domain and
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Fig. 2. SC79 is a pan-Akt activator that speciﬁcally enhances Akt phosphorylation and activation in multiple cell types and in both receptor tyrosine kinase-
and GPCR-mediated signaling. (A) HEK293 cells stably expressing the individual Akt isoforms were treated with indicated amounts of SC79. (B) Indicated cell
lines was treated with SC79 (8 μg/mL) for 30 min and phosphorylation of Akt (Ser473) and its downstream targets, GSK-3β and Foxo1, was analyzed. Total Akt
and actin were used as loading control. (C) Differentiated HL-60 cells was pretreated with SC79 (4 μg/mL) or DMSO for 5 min and then stimulated with fMLP
for indicated time. Phosphorylation of Akt (Ser473) was analyzed as described above. (D) dHL60 were stimulated as described above. Total cell lysate,
cytosolic, and membrane fractions were resolved by SDS/PAGE and analyzed for phospho-Akt (S473), Total Akt, Tubulin (cytosolic marker), and Orai1
(membrane marker) by Western blotting as described in Fig. 1F.( E) Pretreatment of SC79 prevented PtdIns(3,4,5)P3-mediated membrane translocation of Akt
PH but not Itk PH domain. (F) SC79 led to dissociation of membrane-bound Akt PH but not Itk PH domain.
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formation, leading to hyperactivation of Akt. To determine
whether SC79 directly interacts with the Akt-PH domain, we
performed an in vitro binding assay with PtdIns(3,4,5)P3-coated
beads. In the presence of increasing amounts of SC79, Akt-PH-
EGFP brought down by PtdIns(3,4,5)P3 beads was found to be
reduced, indicating that SC79 could directly bind to PH domain
and compete with PtdIns(3,4,5)P3 for such binding (Fig. 3 A and
B). In contrast to Akt PH domain, the in vitro PtdIns(3,4,5)P3
binding capacity of Itk PH domain was unaffected by SC79, al-
though Itk PH domain manifested a relatively higher afﬁnity to-
ward PtdIns(3,4,5)P3 compared with Akt-PH domain (Fig. 3C).
The structure of Akt PH domain has been reported (21).
PtdIns(3,4,5)P3 binds to a shallow pocket in the Akt PH domain
largely mediated through several salt bridges between the phos-
phate groups and basic residues in the protein. Molecular
docking of Akt-PH domain with SC79 revealed that SC79 binds
to the same PtdIns(3,4,5)P3 binding pocket (Fig. 3D). By per-
forming circular dichroism (CD) spectroscopy, we further ex-
amined whether the binding of SC79 to the PH domain can alter
the overall structure of Akt. Far-UV CD spectra were recorded
for full-length human Akt1 in the presence or absence of SC79
(Fig. 3E). The overall secondary structural content of Akt1 was
decreased by 4.3% because of ligand binding at both 25 μM and
50 μM concentrations (Fig. 3E and SI Appendix, Table S5). At 25
μM, SC79 binding resulted in a decrease in α-helical content by
17% and an increase in β-strand content by 19% compared with
Akt1 alone (Fig. 3E and SI Appendix, Table S5). These results
indicate that SC79 can physically interact with and modulate the
structure of Akt.
SC79 signiﬁcantly increased the level of Akt phosphorylation.
One possibility is that, in the presence of SC79, the phosphory-
lated Akt could be more resistant to dephosphorylation by cel-
lular phosphatases. To test this possibility, we examined whether
SC79 affects Akt dephosphorylation by using an in vitro assay.
When the cytosolic extract of HEK293 cells was incubated at
37 °C, a dramatic dephosphorylation of T308 ensued, whereas
that of S473 was progressed in a relatively slower kinetics. Under
this condition, neither the cytosolic extract from SC79 pretreated
cells nor addition of SC79 to the cell lysate attenuated de-
phosphorylation of either T308 or S473 site (Fig. 3F).
To provide direct evidence that SC79-bound Akt adopts a
conformation more amenable to be phosphorylated by upstream
kinases, we explored the effect of SC79 on Akt phosphorylation
by using a cell-free assay. Unphosphorylated Akt was immuno-
precipitated from the lysate of serum-starved cells. In vitro
phosphorylation by puriﬁed PDK1 was conducted in the presence
or absence of SC79. This assay revealed that SC79 could enhance
Akt phosphorylation at T308 site by PDK1. Interestingly, when
T308 site was highly phosphorylated, the phosphorylation at S473
site was also dramatically increased in the absence of any PDK2
kinases (Fig. 3G). The in vitro autophosphorylation at S473 site,
which depends on T308 phosphorylation, has been reported (22).
Thus, our ﬁnding is consistent with this report and supports
a positive role for SC79 in T308 phosphorylation by PDK1.
SC79 Reduces Neuronal Excitotoxicity and Prevents Stroke-Induced
Neuronal Death. Next, we determined whether SC79-induced Akt
activation could recapitulate the physiological function of Akt
signaling. Because Akt deactivation is a causal mediator of
neuronal death in various neurological diseases, we investigated
whether SC79 can suppress such pathological neuronal death by
preventing Akt deactivation. We ﬁrst examined the effect of
SC79 on neuronal death elicited by glutamate excitotoxicity.
Excitotoxicity-induced neuronal death is a unique type of cell
death that is mainly mediated by N-methyl-D-aspartate (NMDA)
receptors (3, 23–25). Akt deactivation is a causal mediator of
excitotoxicity-induced neuronal death (26). Treatment of cultured
cortical neurons with Akt activator SC79 markedly enhanced Akt
phosphorylation without altering total Akt levels (Fig. 4A). Sim-
ilarly, SC79 treatment substantially reduced the death of
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to an active conformation, leading to
hyperactivation of Akt. (A) Both Akt-PH
domain and Itk-PH domain could bind
to PtdIns(3,4,5)P3. (B) SC79 inhibited PtdIns
(3,4,5)P3 binding function of Akt PH do-
main. (C) SC79 did not affect the PtdIns
(3,4,5)P3 binding function of Itk PH domain.
(D) In silico docking of SC79 ligand onto the
Akt PH domain structure. (Left)D o c k e dS C 7 9
ligand (rendered red) onto crystal structure
of Akt PH domain (PDB ID code: 1UNR,
rendered marine). Shown in “wheat” color is
the IP4 ligand that docks at the site almost
similar to the SC79 binding site. Highlighted
in yellow is the residue surface located ad-
jacent to the SC79 binding site that exhibits
signiﬁcant interaction with ligand SC79.
(Right) Zoomed region, as in Left, shows
docked SC79 ligand and interaction residue
R25. (E) CD spectra of human Akt1 and its
complex with SC79. An overlay of CD spec-
tra from 5 μM human Akt1 (shown in black)
alone and in the presence of SC79 of 25 μM
(shown in red) or 50 μM (shown in blue)
collected at 25 °C is shown. Baseline was
corrected for buffer contribution. (F) SC79
did not affect Akt dephosphorylation
in vitro. HEK293 cells grown in serum-rich
medium were treated with DMSO or SC79
(4 μg/mL) for 20 min. Cells were lysed on ice in a control buffer devoid of phosphatase inhibitors or supplemented with SC79 (4 μg/mL). After centrifugation at
4 °C, the lysates were kept on ice (time 0 min) or incubated at 37 °C for indicated time points. The kinetics of Akt dephosphorylation at T308 and S473 was
determined by Western blot. (G) SC79 directly enhanced Akt phosphorylation by puriﬁed recombinant PDK1 in vitro.
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cellular morphology and nuclear staining (26) (Fig. 4B).
To ascertain whether SC79 can lead to Akt hyperactivation
and prevent glutamate-mediated neurotoxicity in intact organ-
isms, an ischemic stroke model was used. We subjected mice to
middle cerebral artery occlusion (MCAO), which elicits sub-
stantial cell death in the area of the occlusion. Most clinical
symptoms of stroke, such as paralysis, aphasia, visual distur-
bance, and memory loss, are caused by neuronal death elicited by
oxygen-glucose deprivation (OGD), which is a result of lack of
blood ﬂow. Stroke-initiated OGD in affected brain regions
induces a dramatic elevation of glutamate in the synaptic clefts
that, in turn, causes massive excitotoxicity-elicited neuronal cell
death (27, 28). Akt was identiﬁed as a potential target for
treating stroke-induced neuronal death (29–32). Consistently,
i.p. pretreatment with SC79 in mice effectively prevented stroke-
induced Akt deactivation (Fig. 4 C and D). Consequently, it
provided protection from excitotoxicity-induced brain damage in
both the cortical area and striatum. The effect of SC79 was
potent, with a single dose of SC79, 0.04 mg/g of body weight
(equivalent to 0.5 μM), reducing the neocortical lesion size by
35% 24 h after MCAO and more than 40% 1 wk after MCAO
(Fig. 4E). More drastic effect was observed when SC79 was
injected multiple times (Fig. 4F).
Discussion
PtdIns(3,4,5)P3-mediated plasma membrane translocation is
a prerequisite for Akt activation by regulatory phosphorylation.
It is reported that PtdIns(3,4,5)P3–PH domain interaction may
not only bring Akt and PDK1, the kinase involved in Thr308
phosphorylation, to the membrane, but also result in confor-
mational changes of Akt, exposing two residues Thr308 and
Ser473 for phosphorylation (33–35). Nevertheless, whether such
conformational changes alone could contribute to Akt phos-
phorylation and activation is not clear. Here, we demonstrate
that the necessity of Akt membrane recruitment can be bypassed
via chemical-induced allosteric activation of cytosolic Akt. From
a cell-based high-throughput chemical genetic screening, we
identiﬁed an Akt activator, SC79, that speciﬁcally targets Akt PH
domain. SC79 may act similarly to PtdIns(3,4,5)P3 to induce Akt
conformation favorable for phosphorylation. It enabled the cy-
tosolic activation of Akt, bypassing the requirement of PtdIns
(3,4,5)P3-mediated Akt membrane translocation (Fig. 4G). It
has been shown that Akt and PDK1 interact in the cytosol (35).
In the absence of PtdIns(3,4,5)P3, the Akt phosphotylation by
PDK1 in this complex is inhibited by the intramolecular in-
teraction between Akt PH and kinase domain (i.e., unfavorable
conformation for phosphorylation). The binding of PtdIns(3,4,5)
P3 to PH domain was shown to release this intramolecular
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Fig. 4. SC79 suppresses excitotoxicity and alleviates stroke-induced neuronal death. (A) SC79 elevated Akt activation in cultured cortical neurons. All samples
were normalized to the amount of total Akt. Data presented are the means (±SD) of three independent experiments. (B) SC79 suppresses excitotoxicity-
induced neuronal death. Primary neuronal cultures (14 d) were treated with 50 μM glutamate for 40 min, and toxicity was assayed 4 h after glutamate
exposure. Cell viability was assessed by ﬂuorescence microscopy after Hoechst nuclear staining and propidium iodide (PI) staining. At least three separate
experiments were performed with a minimum of 1,000 neurons counted per data point. The results are the means of three independent experiments. Bars
indicate means ± SD. (C) SC79 treatment led to Akt hyperactivation in the brain of live animals. Protein extracts collected from the brain of untreated and
SC79-treated mice were resolved on SDS/PAGE and immunoblotted with indicated antibodies. SC79 was applied via i.p. injection at a concentration of
0.04 mg/g of body weight. Data are from ﬁve independent experiments (mean ± SD). *P < 0.05 (Student t test). (D) SC79 enhanced Akt activity during
neuronal cell death in an in vivo mouse ischemia model. Mice (C57 Black/6) were subjected to permanent focal cerebral ischemia by middle cerebral artery
occlusion (MCAO) for 24 h. Brain slices around ischemic penumbra were prepared, and total and phosphorylated Akt/PKB were analyzed. Data are repre-
sentative of ﬁve experiments. (E) SC79 alleviated stroke-induced neuronal death. Infarct volume was assessed in SC79 treated and Sham-treated control mice
at each indicated time points. Data are from ﬁve independent experiments (mean ± SD). *P < 0.05 (Student t test). SC79 was injected i.p. once (0.04 mg/g of
mouse body weight) 5 min before permanent MCAO. (F) The experiment was conducted as described above except that extra SC79 was injected (0.04 mg/g
of mouse body weight, once per hour for 6 h). (G) Schematic model of SC79-induced Akt hyperactivation.
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Econstraint, thus making it a more favorable conformation. Given
that SC79 acts as a PtdIns(3,4,5)P3 mimetic and induces an Akt
conformational change (Fig. 1 D and E), our results also support
such possibility. We further demonstrated that SC79-induced
Akt activation could recapitulate the primary function of Akt
signaling because it efﬁciently prevented the excitotoxicity-in-
duced neuronal death both in vitro and in vivo. Although the
activation of Akt signaling plays signiﬁcant roles in protecting the
ischemic-injury induced neuronal death, other cellular pathways
and components are also important. Nevertheless, the SC79-in-
duced Akt activation alone manifested a signiﬁcant protection.
Identifying other cellular pathways leading to synergistic pro-
tection in combination with SC79 would be important.
Deactivation of Akt contributes to pathogenesis of numerous
neurological diseases (3–5) and, thus, elevating Akt activity
becomes an obvious clinical strategy to suppress progressive
neuronal death under these pathological conditions. However,
this endeavor has been hindered because of the lack of speciﬁc
Akt activators. Our results suggest that chemical mimetics of
PtdIns(3,4,5)P3, such as SC79, could be explored to develop
legitimate Akt activators. SC79 is relatively unstable in aqueous
environment (SI Appendix, Fig. S13A). Intriguingly, however,
after the removal of SC79, the sustained level of phosphorylated
Akt was observed both in cell culture and in vivo (SI Appendix,
Fig. S13 B and C), indicating that SC79 may act irreversibly.
SC79 contains the chemical moieties (i.e., nitrile group) that
could be modiﬁed and/or reacts with amino acids. Nevertheless,
SC79 appeared to be a relatively safe drug. SC79 treatment, even
at much high dose (0.4 mg/g of body weight), did not induce any
detectable changes in body weight, survival rate, appearance, and
behavior in mice (SI Appendix, Fig. S14). The fact that neuronal
protective effect was achieved by i.p. injection suggests that SC79
also has a good penetration of blood–brain barrier. Therefore,
SC79 can be used as a chemical platform to develop novel drugs
for neurological and other complications (SI Appendix).
Materials and Methods
In this study, infarct volume was used to evaluate MCAO-induced brain
damage. For histological examination of infracted area, mice were deeply
anesthetized either 24 h or 1 wk after permanent MCAO by excess pento-
barbital sodium (100 mg/kg). Upon removal, brains were sectioned coronally
into ﬁve slices of 1 mm thickness starting from the frontal pole by using
a mouse brain matrix (ASI Instruments). Slices were stained with 2% (wt/vol)
2,3,5-triphenyltetrazolium chloride (TTC; Sigma) for 30 min at room tem-
perature. Areas ipsilateral to the occlusion, which were not stained, were
recorded as infarcted. After ﬁxation with 4% paraformaldehyde/PBS, the
unstained area of infarction was measured on the posterior surface of each
coronal section by using an Image J system (Wayne Rasband, National
Institutes of Health). Because of substantial hemispheric swelling after is-
chemia, the corrected infarct volume was calculated by using an indirect
method to compensate for the effect of brain edema. The infarcted area of
the ipsilateral (ischemic) hemisphere (II) was determined by subtracting the
noninfarcted area of the ipsilateral hemisphere (IN) from the total area of
the contralateral (uninfarcted) hemisphere (CT): II = CT − IN. Total infarct
volume was then determined by multiplying the area of infarct for each slice
by the slice thickness (1 mm) and summing for the seven brain slices.
Other materials and methods are presented in SI Appendix. Analysis of
statistical signiﬁcance for indicated datasets was performed by using the
Student t test capability on Microsoft Excel.
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Supplementary Information 
 
Supplementary Discussion 
 
            One caveat of using Akt activator as a drug for neurological disorders is that hyperactivation of 
Akt signaling may induce cancer.  Nevertheless, induction of cancer by elevating PtdIns(3,4,5)P3/Akt 
signaling is a progressive process and usually takes several months or even years.  For example, in 
myeloid-specific PTEN knockout mice, we could not find any tumor until 3 months after the birth.  When 
used as a suppressor of neuronal death caused by glutamate-excitotoxicity, Akt activator will only be 
given for several days, even several hours; thus it is unlikely that this type of treatment will lead to 
tumorigenesis.  Interestingly, it was recently reported that activation of Akt1 decreases mammary 
epithelial cell migration, and Akt1 prevents an epithelial-to-mesenchymal transition that resembles events 
required for metastasis (1, 2).  Another report showed that in some acute myeloid leukemia (AML), 
activation of Akt surprisingly reduced leukemic cell growth by inhibiting FOXO (3), suggesting that Akt 
activator can even potentially be used to treat certain cancers.  
 
  Akt is also a key enzyme involved in other processes such as cell migration, immune cell 
activation, embryonic development, hematopoetic and mesenchymal differentiation, and glucose 
homeostasis, thus SC79 may potentially be used to modulate cell function in other physiological and 
pathological situations such as wound healing, host defense, and blood glucose control in diabetes. For 
example, SC79 may have a potential benefit in regulating glucoregulatory responses and insulin 
sensitivity in type 1 and 2 diabetes. Phosphorylation and deactivation of GSK3b promotes glycogen 
synthesis resulting in decreased blood glucose. Akt-mediated GLUT4 translocation mediates glucose 
transport. GSK3b and FOXO also play a role in expression of genes in gluconeogenesis like G6Pase and 
PEPCK(4).  In innate immunity, activating neutrophil functions by elevating PI3K/Akt pathway using 
PTEN inhibitor has been previously reported (5). SC79 may also offer similar effect by directly activating 
Akt. In addition, SC79 may also be effective in preventing myocardial infarction in heart attack, in which 
the acquired resistance to apoptosis is mediated at least in part by the sustained activation of Akt. Use of 
SC79 could exert a wide range of cardio-protective effects in myocardial ischemia/reperfusion-induced 
injury, myocardial hypertrophy, hypertension and vascular diseases by suppressing cell death and 
inducing angiogenesis by regulating eNOS. 
 
 
Supplementary Methods 
 
A cell-based screening system for detection of Akt plasma membrane translocation.   
Activation of PtdIns(3,4,5)P3/Akt pathway relies on PtdIns(3,4,5)P3-mediated plasma membrane 
translocation of Akt. To visualize the Akt membrane translocation in intact cells, we used the PH-domain 
of Akt (PHAkt) fused with green fluorescent protein (PHAkt-GFP) as a marker for this event. The 120 
amino acids PH domain is from human Akt1 and specifically bind to PtdIns(3,4,5)P3.    Overnight 
starvation in serum-free medium abolished PHAkt-GFP membrane localization in unstimulated cells 
(Figure S1).  Subsequent PHAkt-GFP membrane translocation was triggered by the addition of insulin 
growth factor (IGF) (100 ng/ml).  In the experiment described in Figure S1, we utilized transient 
transfection to deliver PHAkt-GFP construct.   Although we were able to detect robust membrane 
translocation of PHAkt-GFP, variable transfection efficiency and levels of recombinant protein expression 
could be problematic for high-throughput screening.  To circumvent this problem, we generated a stable 
cell line expressing PHAkt-GFP fusion protein.  These cells were healthy and IGF-elicited PHAkt-GFP 
membrane translocation could be easily detected as described in Figure S1 (Figure S2).  More 2 
 
importantly, the expression level of PHAkt-GFP fusion protein was almost the same in each individual cell, 
thus making the automatic imaging analysis feasible.  
 
Screening for inhibitors of Akt plasma membrane translocation.   
To validate our cell based assay for high throughput screening, we first conducted a pilot screening using 
a bioactive compound library (approximately 3000 compounds). The screening was performed at the 
Institute for Chemistry and Cell Biology (ICCB) at Harvard Medical School.  Every step of the 
experiment was handled in a high throughput mode (Figure S3).   Based on our preliminary data, we 
incubated cells which have been serum-starved (0.1% serum) for overnight with chemical compounds for 
30 min before inducing PHAkt-GFP membrane translocation with IGF.  Our goal is to identify compounds 
which directly inhibit PtdIns(3,4,5)P3/Akt signaling pathway.  Thus, we chose to use short incubation 
time to exclude compounds which indirectly block GFP-PH membrane translocation (e.g. via affecting 
transcription or translation).  From the pilot screening, we identified 21 positive hit compounds (Figure S4 
and Table S1).  As expected, several known PI3 kinase inhibitors and compounds that nonspecifically 
inhibit PI3 kinase activity were identified as positive hit compounds, validating our strategy and method 
for high throughput screening.   
We then carried out the high throughput screening using several synthetic compound libraries. The 
ICCB compounds are from a variety of sources including commercial libraries from ChemBridge, 
ChemDiv, Bionet, Maybridge, Peakdale, and CEREP, NIH-NCI collections, libraries that result from 
diversity-oriented organic synthesis (DOS), known bioactive compounds, and historic collections of 
compounds resulting from different synthetic strategies.  When ICCB purchased compound libraries, they 
selected collections that are enriched for complex heterocyclic compounds and compounds of higher 
molecular weight (an average mw of ~350-400 Daltons) because these types of compounds are more 
likely to provide interesting hits in high throughput screens.  In addition, they sought to minimize the 
number of potentially “bad” compounds, those with groups that might make them unstable or toxic.  In 
particular, they eliminated unstable imines, compounds with free carboxyl groups, and compounds with 
building block elements that might chelate metals. Table S2 is a list of libraries used for current screening, 
which include more than 60,000 synthetic compounds.  
The high throughput screening was performed twice to minimize the number of false positive hit 
compounds.  From the first screening, we identified about 446 positive hit compounds and 125 of them 
were confirmed in the second screening (Table S3 and Figure S5).  We later found that 25 of the positive 
compounds could generate auto-florescence and their effect on PH-Akt membrane translocation was in 
fact of the result of the greatly enhanced background florescence (Table S3).  
 
Confirmation of the positive hits by time-lapse fluorescent imaging.  
In this study, more than 60,000 chemical compounds were screened and it is difficult to titrate the optimal 
concentration of each compound.  The compound stocks were stored at 5 mg/ml in DMSO.  In our screen, 
100 nl of compound stock was transferred into a 50 µl assay volume, resulting in a final concentration of 
20 µM for a compound of 500 Daltons. This is a generally utilized concentration at ICCB. One potential 
problem of our screening assay is that the transferred compounds may not be able to diffuse evenly in 
each well due to the relatively short incubation time. Thus, the effect of some positive hit compounds on 
PH-Akt membrane translocation could be result of very high local concentration. In order to select the 
most potent compounds for further characterization, we conducted dose-ranging experiments using live 
cells cultured in 35-mm plate.  
  The initial 125 positive hit compounds identified after the second screening (Figure S5) were 
purchased from ChemBridge, ChemDiv, or Maybridge. The fresh stock solution was freshly prepared in 
DMSO (5 mg/ml).  This stock solution was directly added to culture medium to yield three different final 
concentrations (4, 8, 16 µg/ml).  For time-lapse live cell imaging, HeLa-PH-EGFP cells were plated into a 
35-mm glass-bottom dish (MatTek) and cultured for 24 to 48 hours.  Cells were serum-starved in 2 mL 
Leibovitz L15 medium for 1 to 2 h and the medium was replaced with 1 mL of fresh serum-free Leibovitz 3 
 
L15 medium containing a desired concentration of each compound.  After 30 min pre-incubation, IGF1 (5 
ng/mL) was added and images were taken every 5 to 10 min under a 40× oil objective lens.  The relative 
fluorescent intensity at the membrane versus adjacent cytoplasm was determined.  The compounds that 
led to a greater than 75% inhibition of PH-EGFP membrane translocation at or below 16 µg/ml were 
identified and designated as the confirmed hits.  The representative live images and structure of 55 
confirmed hit compounds were shown in Figure S6 and Figure S7.   
 
SC79-induced cytosolic phosphorylation of Akt analyzed by western blotting.  
Hela cells were serum starved for 1 hr and treated with IGF (100ng/ml) or SC79 (4 µg/ml) for 30 minutes. 
Cells were lysed in Lysis buffer containing 250 mM Sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM 
MgCl2, 1 mM EDTA, 1 mM EGTA supplemented with protease inhibitors. Cells were passed through 
25G needle several times and kept on ice for 20 minutes. Total cell lysate was taken at this point. Cell 
lysates were centrifuged at 100,000g for 30 minutes. Supernatant was collected as the cytosolic fraction . 
Pellet was washed with lysis buffer and represents the membrane fraction. Total cell lysate, cytosolic and 
membrane fractions were resolved by SDS-PAGE and analyzed for phospho-Akt (S473), Total Akt, 
Tubulin (cytosolic marker) and Orai1 (membrane marker) by western blotting.   
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay for cell viability.  
HsSultan or NB4 cells (2.5 × 10
5) were plated in a 24-well plate in 500 μL of phenol red-free RPMI 
medium supplemented with 10% FBS.  After incubation for 24 hours, each compound (8 µg/ml) was 
added and cultured for overnight (16–20 h).  Fifty microliters of MTT solution (5 mg/mL in PBS) were 
added to each well.  Following 2 hrs incubation, the purple formazan crystals were dissolved by directly 
adding in 500 μL of isopropanol with 0.1 M HCl to each well. After clearing the cell debris by 
centrifugation, the absorbance was measured at a wavelength of 570 nm. 
 
In silico docking 
In silico docking calculations were carried out using AutoDock Vina (6) as described elsewhere (7). Three  
dimensional  crystal  structures  of  Protein  Kinase  B/Akt  PH  domain unbound  form  (RCSB  PDB  ID:  
1UNR)  and  inositol-(1,3,4,5)-tetrakisphosphate  (IP4) bound  form  (RCSB  PDB  ID:  1UNQ)  were  
retrieved from Protein Data Bank corrected for bond order and orientation with application of proper 
protonation states used  in docking experiments using MGLTools (v1.5.4) (8). Structural coordinates  of  
ligand  SC79  were  generated  using  Sybyl sketcher module (9) and energy minimized using a standard 
Tripos forcefield (TRIPOS, St. Louis, MI) that employs Powell minimization and simplex optimization 
with the distance dielectric function and an energy gradient of 0.05 Kcal/Mol Å with application of 
Gasteiger charges. Docking of SC79 onto proteins 1UNR and 1UNQ was carried out with similar grid 
dimension of 100 Å × 100 Å × 100 Å. A local optimization and exhaustive search was carried out by 
docking algorithm to find and cluster best docked poses of SC79 onto protein structures. Similar docking 
parameters were applied in both the cases. The best 9 lowest-energy docked poses were identified and 
analyzed.  Ligand IP4 was also docked onto ligand free Akt PH domain structure. As a validation to the 
applied parameters, native ligand IP4 was redocked onto bound PH domain structure that resulted in 
binding to similar pocket with a RMSD of 0.9581Å. Figures were generated using program PyMOL 
(DeLano Scientific, LLC, San Carlos, CA, USA).   
  A flexible grid-based SC79-PH domain docking protocol defined 9 clustered poses for the PH 
domain bound to SC79. Figure 3D illustrates best docked pose of SC79 onto unbound PH domain that 
possessed ∆G of -5.6 kcal/mol. This pose identified residue Arg25 within binding site which exhibits 
numerous interactions with the ligand SC79 including hydrogen bond interaction. Results demonstrate 
that SC79 binds to the similar pocket in unbound PH domain structure as was reported a IP4 binding site 
in bound PH domain structure. This prompted us to investigate about the IP4 binding pocket in unbound 
PH domain. Interestingly, IP4 binding site resembles the SC79 binding site in unbound PH domain 
(Figure 3D, left panel). The SC79 and IP4 ligands compete with each other to occupy a similar binding 4 
 
site onto PH domain. SC79 docking onto IP4 bound PH domain resulted in yielding alternate binding 
pockets of SC79 other than noted above (Figure 3D). Taken together, these docking analyses suggest that 
SC79 binds to PH domain. SC79 binding to IP4 bound PH domain may result in a weaker affinity 
complex.  
 
Circular Dichroism (CD) 
Far-UV CD (260-195 nm) was carried out at 25 °C on a Jasco-810 spectropolarimeter (Jasco, Easton, 
MD) purged with nitrogen gas. Data were acquired in 1-mm quartz cuvette with 1-nm bandwidth, 2-s 
response time, 10 nm/min scan speed, and four scans. Pure N-terminal 6His-tagged recombinant full 
length Human Akt1 was purchased from Millipore (www.millipore.com/catalogue/item/14-279). 
Chemically synthesized and purified SC79 was purchased from ChemBridge. Protein and ligand samples 
were prepared in 50 mM Tris pH 7.5, 150 mM NaCl. Akt1 was incubated with SC79 at 37 °C for 30 min. 
Data sets were acquired in duplicate. Percent secondary structure was determined using programs K2D 
(http://www.embl.de/~andrade/k2d.html) and K2D2 (http://www.ogic.ca/projects/k2d2/). 
 
Neuronal cell cultures and Cytotoxicity  Primary cortical or hippocampal neuronal cultures were 
prepared as previously described (10).  To induce excitotoxicity, the
 cells were prewashed with Tris-
buffered control salt (CSS) solution
 (120 mM NaCl, 5.4 mM KCl, 1.8 mMCaCl2, 25 mM Tris-HCl,
 pH 
7.4, and 15 mM glucose) and treated with CSS containing 50 µM glutamate
 for 40 min, followed by 4 hr 
recovery in regular culture medium.  SC79 (4 μg/ml) was given 15 min before and during glutamate 
treatment. Toxicity was assayed 4 h after glutamate exposure by microscopic examination with computer-
assisted cell counting.  Total and dead cells
 were determined by nuclei staining with Hoechst (0.5 ng/ml) 
and propidium iodide (1 μg/ml), respectively.  After 20 min incubation, the cells were examined under a 
fluorescence microscope
 with excitation at 360 nm.  Cell death was determined as the ratio of dead-to-
total
 cell number and quantified by counting 1,000
 cells.  
 
Permanent focal cerebral ischemia model 
This study was conducted in accordance with the Animal Welfare Guidelines of Tokai University School 
of Medicine, Japan.  The permanent focal cerebral ischemia was induced by middle cerebral artery 
occlusion (MCAO) essentially as described previously(11).  Briefly, mice (C57 Black/6) weighing 17–25 
g were anesthetized with 4% isoflurane/66% N2O/30% O2 and maintained with 1.5% isoflurane.  
Permanent focal ischemia was achieved as follows: a 2-mm hole was drilled at a site superior and lateral 
to the left foramen ovale to expose the left middle cerebral artery.  The proximal portion of the left middle 
cerebral artery (MCA) was permanently occluded over a 1-mm segment distal to the origin of the 
lenticulostriate branches through the use of a bipolar coagulator (12).  SC79 was injected intraperitoneally 
(0.04 mg/g mouse body weight) 5 min before permanent MCAO (Figure 4E).  In another experiment, 
extra SC79 was injected (0.04 mg/g mouse body weight, once per hour for 6 hours) (Figure 4F).   
 
Akt activation in the brain assessed by immunohistochemistry  
The mouse brains were perfused from the apex of the heart with PBS and perfusion-fixed with 4% 
paraformaldehyde in PBS.  They were then immersion-fixed overnight at 4°C in 4% paraformaldehyde 
with rocking and subsequently cryoprotected in 10% (2 hours), 15% (2 hours), 20% (2 hours), and 25% 
(overnight) sucrose in PBS at 4°C.  The slices were then embedded in OCT compound (Miles Scientific) 
and quickly frozen in isopentane.  Coronal frozen sections (10-µm) were prepared on a cryostat and stored 
at -80 °C until use.  The frozen sections were thawed, washed three times in PBS, permeabilized with 
0.1% Triton X-100/PBS at room temperature for 5 min, and then blocked in 5% skim milk/3% BSA/PBS 
for 60 min.  Total and phosphorylated Akt/PKB were detected using anti-Akt and anti-Phospho-Akt 
(Ser473) antibodies (Cell Signaling,), respectively. The slides were incubated with primary antibodies 
(1:200) at 4 °C overnight, and with the secondary antibodies at room temperature for 2 h, and 
immunoreactivity visualized by the ABC method (10).   5 
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 Table S1. Positive hit bioactive compounds identified from the pilot screening. 
Plate # Well # Name Target or biological activity Molecular formula Molar weight Source  
500 E17 Ciprofloxacin hydrochloride Antibiotics; Inhibit bacterial DNA rewind C17N3O3F 312.99234 NINDS
500 F15 Econazole nitrate  Antifungal drug; Inhibit fungal cell membranes C18H15N2OCl3 380.02496 NINDS
500 H18 Miconazole nitrate Antifungal drug; Inhibit fungal cell membranes C18H14N2OCl4 413.98596 NINDS
500 I15 Gossypol  Polyphenols; Inhibitor of dehydrogenases C30H30O8 518.1939 NINDS
500 M20 Tamoxifen citrate Competitive antagonist of estrogen receptor C26H29NO 371.2248 NINDS
500 B13 Gentian violet Antifungal and bactericidal agent   C25H30N31+ 372.2439 NINDS
500 K11 Centrimonium bromide  Antiseptic agent; Cationinc surfactants C19H42N1+ 284.33173 NINDS
500 O8 Phenylmercuric acetate  Fungicide; Herbicide C8H8O2Hg 338.023 NINDS
1362 I17 NSC-95397  Inhibitor of Cdc25 dual specificity phosphatases C14H14O4S2 310.03336 BIOMOL
1362 K19 BAY 11-7082  Inhibitor of NF kappa B activation C10H9NO2S 207.0354 BIOMOL
1362 N13 Wortmannin  Inhibitor of phosphoinositide 3 kinases C23H24O8 428.1471 BIOMOL
501 E17 Merbromin  Antiseptic agent C20O6Br2Hg2- 695.77686 NINDS
500 E16 Hexylresorcinol   Antiseptic and antihelmintic agent C12H18O2 194.13069 NINDS
501 B08 Cetylpyridinium chloride  Antiseptic and antibacterial agent C21H38N1+ 304.3004 NINDS 501 B08 Cetylpyridinium chloride  Antiseptic and antibacterial agent C21H38N1+ 304.3004 NINDS
1362 E19 Ro 31-8220  Selective PKC inhibitor C25H23N5O2S 457.15714 BIOMOL
1362 J07 Staurosporine ATP-competitive protein kinase inhibitor C28H26N4O3 466.53 BIOMOL
503 G17 Harmalol hydrochloride  Alkaloids from plants C12H12N2O 200.09496 NINDS
502 D20 Celastrol Antioxidant and anti-inflammatory agent C28H36O4 436.2613 NINDS
1569 L10 Ellipticine  Anticancer agent;Binds to topoisomerase II C17H14N2 246.11569 Prestwick
1362 F09 Quercetin dihydrate Antioxidant flavonoid;Inhibitor of  cAMP-phosphodiesterases C15O7 291.9644 BIOMOL
1362 M5 LY294002 Inhibitor of phosphoinositide 3 kinases C19H17NO3 307.343 BIOMOL
     Table S2.  Compound libraries used for primary and secondary screenings.  
Library name # of Compounds Plate Numbers # of Plates
Bioactive  Biomol ICCB Known Bioactives 480 1361-1362 2
Compounds NINDS Custom Collection 1,040 500-503 4
Prestwick 1 Collection 1,120 1568-1571 4
ChemBridge 3 19,560 1577-1606 30
Synthetic  ChemDiv 4 14,677 1607-1648 42
Compounds Maybridge 5 3,212 1661-1670 10
ChemDiv 3 16,544 1473-1519 47
Maybridge 1 8,800 542-563 22
Total number of chemicals 65433 Table S3 Page 1
Table S3. Positive hit compounds identified from the primary and secondary screenings.
ID Source Reagent Source ID Mol. Formula Mol. Weight PubChem CID Autofluorescence Toxicity  ID
SC1 545 H12 Maybridge Maybridge BTB 06587 C9NO4 191 2799766 SC1
SC2 550 I05 Maybridge Maybridge CD 08589 C9H4N5O4SF3 335 2805154 SC2
SC3 550 O05 Maybridge Maybridge CD 08635 C16H22N2O2S2 338 2805164 SC3
SC4 554 P07 Maybridge Maybridge KM 02595 C8H13NO2S3 251 2778657 SC4
SC5 554 P22 Maybridge Maybridge KM 03776 C12H13NO3S2 283 2820297 * SC5
SC6 558 H11 Maybridge Maybridge RDR 03078 C6H12N2S2 176 167013; 167304; 123256; 105062; 522634; 313; 10313041  SC6
SC7 561 H02 Maybridge Maybridge S 02113 C14H15NO2 229 300890 SC7
SC8 561 K13 Maybridge Maybridge RJC 03273 C7H5O2Br 200 2729629 SC8
SC9 1476 B07 ChemDiv ChemDiv 2548-0771 C18H19NO5 329 4606022 SC9
Plate/Well #
SC9 1476 B07 ChemDiv ChemDiv 2548-0771 C18H19NO5 329 4606022 SC9
SC10 1477 C02 ChemDiv ChemDiv 3182-0185 C13H21N2S2
1+ 269 5475033; 5749630; 102370; 7015549  * SC10
SC11 1478 C16 ChemDiv ChemDiv 3448-1880 C18H14N2O5 338 1917689; 703540; 1917688  * SC11
SC12 1479 N21 ChemDiv ChemDiv 3888-0510 C17H13NO3S 311 5724532; 6740709; 5398661  SC12
SC13 1481 H17 ChemDiv ChemDiv 4340-1702 C21H17N2O3SBr 456 1337448; 1337447  * SC13
SC14 1481 H22 ChemDiv ChemDiv 4379-0593 C16H12N2O2S4 388 2194030 * * SC14
SC15 1483 O06 ChemDiv ChemDiv 4663-0305 C12H7O2Br 262 749613 SC15
SC16 1490 I04 ChemDiv ChemDiv 6234-0158 C17H17N4S2F 360 7045555; 3357152; 7127443  SC16
SC17 1491 N08 ChemDiv ChemDiv 6658-0003 C23H28N2O 348 2952775; 961714; 961713  * SC17
SC18 1491 N15 ChemDiv ChemDiv 6623-0252 C15H17NO 227 781226; 2063512; 781227  * SC18
SC19 1498 A09 ChemDiv ChemDiv C301-2030 C14N2OCl2 282 584802 * SC19
SC20 1498 G02 ChemDiv ChemDiv C301-3578 C14NO2Cl 249 768385 SC20
SC21 1498 I18 ChemDiv ChemDiv C306-0545 C25HN3O2S 407 6621759 SC21
SC22 1511 J19 ChemDiv ChemDiv K788-0502 C26N2O2S 404 4058887 SC22
SC23 1515 D07 ChemDiv ChemDiv 7286-2245 C15H14N4O3S 326 970664 SC23
SC24 1515 M03 ChemDiv ChemDiv E746-0124 C18H19N3O2S 337 6624952 SC24
SC25 1517 D06 ChemDiv ChemDiv D053-0021 C13H11N3O4SCl2 375 2987701 * SC25
SC26 1577 C20 ChemBridge 5106399 C13H9NO4 243 2192517 SC26
SC27 1577 D22 ChemBridge 5193093 C10H7NOS 189 1626686; 2832913  * SC27
SC28 1578 B03 ChemBridge 5140994 C8H8N4 160 6787450; 6863956; 5544086  * SC28 SC28 1578 B03 ChemBridge 5140994 C8H8N4 160 6787450; 6863956; 5544086  * SC28
SC29 1578 B09 ChemBridge 5214970 C15H17NO 227 781226; 2063512; 781227  * SC29
SC30 1578 B15 ChemBridge 5216515 C10H13O2Br 244 787529 SC30
SC31 1578 F19 ChemBridge 5260273 C16H23NO2 261 792319; 792320; 2838039  SC31
SC32 1578 I07 ChemBridge 5115555 C27H35N5S 461 6759337; 1377982; 5717379; 2828280  * SC32
SC33 1578 N08 ChemBridge 5169046 C11H12N2O2 204 5569250; 6611042; 5718022  SC33
SC34 1579 C19 ChemBridge 5264570 C16H13NO 235 2177126; 2838279; 2177244  SC34
SC35 1579 E22 ChemBridge 5176963 C6H5NS3 187 2832072 * SC35
SC36 1579 F18 ChemBridge 5240810 C10H8N2O4 220 747593; 1911041; 1911042  * SC36
SC37 1579 N16 ChemBridge 5240765 C18H14N2O4 322 6746064; 5417561; 5596031  SC37
SC38 1580 B08 ChemBridge 5317697 C9HN2OS 185 794582 SC38
SC39 1581 A12 ChemBridge 5431041 C17H18NOF3 309 783606 SC39
SC40 1582 E17 ChemBridge 5710104 C8H7NO3 165 869076; 96000; 11897671  SC40
SC41 1582 L14 ChemBridge 5459675 C17H21NO2 271 11921442; 6456397; 11921441  * SC41
SC42 1582 M19 ChemBridge 5718756 C16H13N5O2S 339 6745067; 5336479  SC42
SC43 1583 F15 ChemBridge 5735144 C16H12N2O2 264 869358; 869359; 2865647  SC43 Table S3 Page 2
SC44 1584 A21 ChemBridge 5787636 C22H27NO4 369 5508822; 6758018; 5726290  * SC44
SC45 1585 D07 ChemBridge 5809904 C17H12N2O4 308 1916528; 873244  SC45
SC46 1585 I05 ChemBridge 5943536 C18H12N2O3S2 368 9586234; 2235899  SC46
SC47 1586 G16 ChemBridge 6274843 C19H14N3O4S2Cl 447 1348278; 1348277; 2274928  * SC47
SC48 1587 F16 ChemBridge 6598710 C10NOSCl2 252 759209 SC48
SC49 1588 G16 ChemBridge 6888464 C18H11N3O6 365 1323123 SC49
SC50 1590 I16 ChemBridge 7564073 C14H23NO3S 285 623015 SC50
SC51 1593 E15 ChemBridge 7693384 C15H16NOCl 261 2948191; 828623; 828622  SC51
SC52 1593 O07 ChemBridge 7772407 C17H20N2O3S 328 2953048 * SC52
SC53 1600 N13 ChemBridge 7992444 C12H16N2O2 220 2985018 SC53
SC54 1607 B19 ChemDiv ChemDiv 0455-0021 C13H21N2O2
1+ 237 4597466; 6160337  * SC54
SC55 1607 K10 ChemDiv ChemDiv 0149-0135 C21H28O3 328 5239155 SC55 SC55 1607 K10 ChemDiv ChemDiv 0149-0135 C21H28O3 328 5239155 SC55
SC56 1607 M10 ChemDiv ChemDiv 0157-0001 C9O2Cl 175 87326 * SC56
SC57 1607 O08 ChemDiv ChemDiv 0139-0206 C7H3NO2Cl4 273 676444 SC57
SC58 1614 A09 ChemDiv ChemDiv 4767-1305 C24H26N2O6S 470 1009503; 1809094  * SC58
SC59 1614 K07 ChemDiv ChemDiv 4762-1092 C20H20N3O2SF 385 No ID   SC59
SC60 1617 H15 ChemDiv ChemDiv 6383-0891 C17H18N3Cl 299 975900 * SC60
SC61 1617 K01 ChemDiv ChemDiv 6177-0034 C20H20N2O2 320 7114457; 675011; 7114459; 5291898; 7114458; 2973216  SC61
SC62 1618 N08 ChemDiv ChemDiv 7202-2080 C20H16N4O4S2 436 22525620; 3318217; 5791770    SC62
SC63 1618 N18 ChemDiv ChemDiv 7218-1489 C13H12N2O2S2 292 22332416 SC63
SC64 1618 P08 ChemDiv ChemDiv 7202-2246 C16H9N4O3S3 401 24283764; 7728365  SC64
SC66 1621 D01 ChemDiv ChemDiv C151-0032 C18H16N2O 276 4137609; 6018993  SC66
SC67 1621 P05 ChemDiv ChemDiv C151-0517 C18H17N3O 291 702066; 2265242; 2265240  SC67
SC68 1621 P07 ChemDiv ChemDiv C151-0796 C15H17NO 227 5050194 SC68
SC69 1622 C10 ChemDiv ChemDiv C201-0114 C11N2O3 208 No ID SC69
SC70 1628 N07 ChemDiv ChemDiv C700-1471 C20N3O3S 362 20876818 SC70
SC71 1648 C05 ChemDiv ChemDiv K906-4279 C10H12N2O 176 20969907 SC71
SC72 1648 C13 ChemDiv ChemDiv K939-0016 C14H10N2O 222 5398228; 260652; 16039283  SC72
SC73 1648 M09 ChemDiv ChemDiv K915-1566 C24H28N3O3Cl 441 3241960 SC73
SC74 1661 C05 Maybridge Maybridge AW 00693 C15H14N4OClF3 358 2795918 SC74
SC75 1661 J01 Maybridge Maybridge BTB 08680 C17H12N2O3F2 330 2801021 SC75 SC75 1661 J01 Maybridge Maybridge BTB 08680 C17H12N2O3F2 330 2801021 SC75
SC76 1662 F06 Maybridge Maybridge GK 03531 C14H11N6OF3 336 2809005; 9583713; 5714465  SC76
SC77 1662 J21 Maybridge Maybridge GK 02921 C14H12N3O2F3 311 2808617 SC77
SC78 1662 P03 Maybridge Maybridge FM 00024 C11H15NO2 193 11859264; 16100370; 2807445  SC78
SC79 1663 O19 Maybridge Maybridge HTS 02701 C17H17N2O5Cl 364 6975756; 6975759; 6975757; 2810830; 6975758  SC79
SC80 1664 P13 Maybridge Maybridge HTS 12963 C8HN2OS 173 173760 SC80
SC81 1668 B19 Maybridge Maybridge SEW 03790 C12H12O4S 252 591564 SC81
SC82 1668 D19 Maybridge Maybridge SEW 03825 C8H3N2SCl 194 2740505 SC82
SC83 1668 E07 Maybridge Maybridge S 15443 C11N2O2 192 2738086 SC83
SC84 1668 K16 Maybridge Maybridge SEW 00543 C10H9OSCl 212 6925757; 6925758; 2739084  SC84
SC85 1669 D06 Maybridge Maybridge SPB 05266 C15H8N4O2Cl2 346 628891 SC85
SC86 1585 E12 ChemBridge 6082181 C18 H16 N4 O2 S2 384 No ID SC86
E1 1481 E10 ChemDiv ChemDiv 4286-0237 C18H16N2O2 292 6620710; 5334000  E1
E2 1484 N01 ChemDiv ChemDiv 4999-0666 C18H16N2O4S 356 16193244; 6620788  * E2
E3 1607 N06 ChemDiv ChemDiv 0645-0166 C18N2O2 276 202512 * E3
E4 1473 D13 ChemDiv ChemDiv 0388-0143 C18H15NO2 277 67273 E4 Table S3 Page 3
E5 1476 C14 ChemDiv ChemDiv 2374-0075 C21H23NO2 321 4533882; 11878901; 11878907; 11878905; 11878903 * E5
E6 1487 A14 ChemDiv ChemDiv 5701-0577 C22H25NO4 367 4602281; 1854370  * E6
E7 1624 O09 ChemDiv ChemDiv C301-5476 C9N8O 236 3163523 E7
E8 1669 K04 Maybridge Maybridge SPB 00784 C20H23N3OS 353 2743318 E8
E9 1476 A20 ChemDiv ChemDiv 2422-1298 C18NOS 278 1730434; 744351  * E9
E10 1477 M05 ChemDiv ChemDiv 3062-0036 C18H23NO2S2 349 1514885; 1514884; 3071511  E10
E11 1481 I10 ChemDiv ChemDiv 4286-0239 C17H14N2O2 278 14741964; 6620717  * E11
E12 1580 H11 ChemBridge 5279826 C11O2 164 765984 E12
E13 1608 P13 ChemDiv ChemDiv 1683-1038 C17N2O3S 312 668008; 668009  * E13
E14 1612 P06 ChemDiv ChemDiv 4286-0232 C16H14N2O 250 5339421; 5416091; 6801758  * E14
E15 1639 B02 ChemDiv ChemDiv E781-0267 C17H21N6OCl 360 16456505 E15
E16 1669 O21 Maybridge Maybridge SPB 00465 C12H9N2O2SClF2 318 2743188 E16 E16 1669 O21 Maybridge Maybridge SPB 00465 C12H9N2O2SClF2 318 2743188 E16
E17 544 K16 Maybridge Maybridge BTB 04176 C15H11NOSCl3F 377 2798260 E17
E18 545 J10 Maybridge Maybridge BTB 06548 C17H13N5O 303 2799743 E18
E19 545 L09 Maybridge Maybridge BTB 06196 C13H9NOClF 249 705916 * E19
E20 550 M11 Maybridge Maybridge CD 09133 C10H11O6S3F3 380 2805283 E20
E21 554 A04 Maybridge Maybridge KM 01302 C9N4O 180 2735244 E21
E22 1474 D07 ChemDiv ChemDiv 1326-0389 C17H12NO2Cl 297 598489 E22
E23 1502 O11 ChemDiv ChemDiv C620-0170 C19H15N2O2Br 382 6622833 E23
E24 1517 D20 ChemDiv ChemDiv D090-0079 C14H17N2Cl 248 846381; 3138840; 846380  E24
E25 1577 A04 ChemBridge 5108485 C17H17NO2 267 744328; 744324  * E25
E26 1581 M02 ChemBridge 5406375 C11H9NO3 203 5397103 E26
E27 1582 L05 ChemBridge 5402066 C16H11NO3 265 5403890; 768328  E27
E28 1586 L12 ChemBridge 6717002 C14H14NO4S2Br 403 5733354; 2911684  * E28
E29 1610 A10 ChemDiv ChemDiv 3178-0151 C17H14O5 298 743982 E29
E30 1624 B02 ChemDiv ChemDiv C355-1313 C21N4O7S2Cl 519 No ID * E30
E31 1639 J17 ChemDiv ChemDiv E771-0423 C19H23N3O 309 20916544 * E31
E32 1641 F12 ChemDiv ChemDiv G017-4142 C16H22N2O3S3 382 20937318 E32
E33 1642 I06 ChemDiv ChemDiv G125-0751 C25H30N4O2S 450 20940800 E33
E34 1643 O03 ChemDiv ChemDiv G278-0048 C17H21N3O2S 331 20947619 E34
E35 1645 D06 ChemDiv ChemDiv K405-2825 C16H16N5Cl 313 17017244 E35 E35 1645 D06 ChemDiv ChemDiv K405-2825 C16H16N5Cl 313 17017244 E35
E36 1647 M07 ChemDiv ChemDiv K786-8481 C25N5O2Cl2 472 15994483 E36
E37 1663 E03 Maybridge Maybridge HTS 01393 C18H19N3OF4 369 2810103; 7189247; 7189249  E37
E38 1669 A20 Maybridge Maybridge SPB 02768 C14H15N2O2SBr 354 2744343 E38
E39 1669 K02 Maybridge Maybridge SPB 00548 C16H14N3OSCl 331 2743236 E39
E40 1669 P15 Maybridge Maybridge SPB 04530 C16H15N3O3S 329 2745327 E40
E41 1670 C01 Maybridge Maybridge SPB 07631 C18H19NO 265 2746994 E41PH-PLCd-GFP 
First Second HeLa NB4 HsSultan 8 mg/ml 4 mg/ml
SC2 + + - - - 0.13 ++++++ 0.19 +++++ + + + + -
SC3 + + - - - 0.76 + 0.79 + - + + - +
SC4 + + - - - 0.25 +++++ 0.28 +++++ + + + + +
SC5 + + - - + 0.12 ++++++ 0.20 +++++ + + + + +
SC7 + + - - - 0.13 ++++++ 0.32 ++++ + + + + +
SC16 + + - - + 0.20 +++++ 0.45 ++++ + + + + +
SC17 + + - - + 0.12 ++++++ 0.19 +++++ + + - - -
SC25 + + - - + 0.13 ++++++ 0.20 +++++ + + + + -
SC26 + + - - - 0.13 ++++++ 0.84 + + + - + -
SC30 + + - - - 0.73 ++ 0.69 ++ - + - + -
SC31 + + - - - 1.05 +/- 1.02 +/- + - - + +
SC33 + + - - - 0.89 + 1.16 +/- - - - - -
SC35 + + - - + 0.14 ++++++ 0.33 ++++ + + - - -
SC36 + + - - + 0.82 + 0.83 + + + + + +
SC38 + + - - - 0.71 ++ 0.90 +/- + + + + +
SC39 + + - - - 0.69 ++ 0.84 + + - - + +
SC43 + + - - - 0.89 + 0.75 + + + + + +
SC44 + + - - + 0.83 + 1.02 +/- + + + - -
SC45 + + - - - 0.85 + 1.00 +/- + + + + +
SC46 + + - - - 0.51 +++ 0.37 ++++ - + - - -
SC51 + + - - - 1.02 +/- 0.68 ++ + + + - -
SC55 + + - - - 0.80 + 0.62 ++ + + + + +
SC57 + + - - - 0.20 +++++ 0.70 ++ + + - + +
SC59 + + - - - 0.27 +++++ 0.38 ++++ - - - + -
SC62 + + - - - 0.32 +++++ 0.27 +++++ + - - + +
SC64 + + - - - 0.27 +++++ 0.25 +++++ + - - - -
SC69 + + - - - 0.90 +/- 0.96 +/- + + + - -
SC74 + + - - - 0.74 ++ 0.26 +++++ + + + - -
SC75 + + - - - 0.97 +/- 0.99 +/- + + + - -
SC79 + + - - - 0.90 +/- 0.83 + increase increase increase increase increase
SC80 + + - - - 0.91 +/- 0.98 +/- - + + - -
SC83 + + - - - 0.76 + 0.82 + + + - + +
SC84 + + - - - 0.89 + 0.88 + + + + + +
E7 + + - - - 1.02 +/- 0.96 +/- + + - + +
E8 + + - - - 0.84 + 0.69 ++ + + - + +
E10 + + - - - 0.61 ++ 0.44 ++++ + + + + -
E12 + + - - - 0.36 ++++ 0.18 +++++ + + + + +
E17 + + - - - 0.80 + 0.74 ++ + + + + +
E19 + + - - - 0.83 + 0.66 ++ + - + + +
E20 + + - - - 0.57 +++ 0.51 +++ - - - + +
E29 + + - - - 0.44 ++++ 0.35 ++++ + - - + +
E40 + + - - - 1.05 +/- 0.94 +/- + + + + +
SC1 + + - - - 0.13 ++++++ 0.27 +++++ - + + + +
SC11 + + - - + 0.27 +++++ 0.41 +++ + + - + +
SC13 + + - - + 0.19 ++++++ 0.21 +++++ + + + + +
SC19 + + - - + 0.12 ++++++ 0.19 +++++ +/- + - + -
SC23 + + - - - 0.21 +++++ 0.38 ++++ + + - + -
SC27 + + - - + 0.14 ++++++ 0.35 ++++ + + + + -
SC49 + + - - - 0.58 +++ 1.08 +/- + + + + +
SC63 + + - - - 0.69 ++ 0.83 + + + + + +
SC66 + + - - - 0.15 ++++++ 0.40 ++++ +/- + - + +
SC67 + + - - - 0.21 +++++ 0.57 +++ - - - + +
SC86 + + - - - 0.55 +++ 1.05 +/- +/- - - + +
E26 + + - - - 0.88 + 0.92 +/- +/- - + + +
WTM (100 nM) + + - - - 0.94 +/- 0.84 + + + + + +
DMSO - - - - - 1 +/- 1 +/- - - - - +
+
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Table S4.  Characterization of the confirmed positive hit compounds.  
a  ‘+’ indicates inhibition of membrane translocation greater than 75% of control.
b  For morphological observation of adherent cells, HeLa cells were plated in 24-well culture dish and grown overnight in serum rich condition.  Following chemical 
addition (8g/ml), the bright field images of live cells were taken at 30 min and 6 hr.  ‘+’ indicates chemicals that lead to morphological changes and/or detachment.  
For MTT-based cell viability assay for suspension cells, the readings (absorbance 570 nm) from triplicates were averaged and normalized against DMSO-treated group.  
The relative inhibitory activity was presented as following: +/- (0.9-1.16); + (0.75-0.90); ++ (0.60-0.75); +++ (0.45-0.60); ++++ (0.30-0.45); ++++ (0.15-0.30); ++++++ 
(<0.15).
+
+
-
Effect on Akt phospharalation (-, no effect; +, inhibited)
(HL60 cells)
ID
HsSultan cells NB4 cells
MTT assay Table S5. The secondary structures of human Akt1 and its complex with SC79 were analyzed using circular dichroism (CD) spectroscopy.
   Akt1 (5mM)     Akt1+ SC79 (25 mM)       Akt1+ SC79 (50 mM)
% alpha-helix 30 25 26
% beta-sheets 16 19 18
% random coil 54 56 56
Sum (sec. structural content) 46 44 44
Random coil 54 56 56
% Loss in sec. structure upon SC79 binding 4.3 4.31 0 3 5 30 20 10 Min
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Figure S1.  Insulin-like growth factor 1 -induced Akt plasma membrane translocation.  Hela cells were transfected with a construct 
expressing the PH-domain of Akt fused with enhance green fluorescent protein (PH-EGFP).   Using Lipofectamine 2000 reagent (Invitrogen), 
transfection efficiencies of >80% were routinely obtained.  Cells were starved in serum free medium overnight and the Akt membrane 
translocation was triggered by IGF1 (final concentration 100 ng/ml).   For LY294002 treatment, the drug (20 µM) was added to the culture 
medium 60 min before the IGF1 stimulation.  (A) Confocal fluorescent images of PH-EGFP were captured at each of the indicated time 
points.  Each experiment was repeated at least three times and virtually the same results were obtained each time.  The figure shows the 
results of a representative experiment.  (B) Quantitative analysis of the IGF1-elicited translocation of PH-EGFP.  The average membrane 
fluorescence intensities in (A) were measured with IPLab software as previously described.  The arbitrary number of the membrane
fluorescence intensity in each individual cell was normalized to the total fluorescence intensity of the cell.  Intensities from “0 min” frame 
was subtracted from each of the other frames and plotted as a function of time after IGF1 stimulation.  The results are the means (± SD) of 20 
transfected cells in three independent experiments.Figure S2. Generation of a stable HeLa cell line expressing Akt-PH-EGFP fusion protein. To 
generate a stable HeLa cell line, the plasmid containing PH-EGFP driven by chicken beta-globin 
promoter was co-transfected with pcDNA3.1.  The transfected cells were selected in the presence of 
G418 (2 mg/ml) for two weeks, and the stable PH-EGFP expressing clones were isolated and maintaned 
in the medium containing G418 (200 mg/ml).  The membrane translocation of PH-EFP, as described in 
Figure S1, was conducted in 384-well plate.  Serum-starved cells were fixed in 3 % PFA (no IGF) or pre-
treated with DMSO or PI3K inhibitors; wortmannin (200 nM) and LY294002 (20 mM) for 30 min and 
stimulated with IGF1 (100 ng/ml) for additional 15-30 min before fixation.  Images were taken using a 
fully automated fluorescent microscope, Image Xpress Micro (Molecular Dynamics). 
No IGF DMSO + IGF
Wortmannin + IGF LY294002 + IGFFluorescent image acquisition  Image Xpress Microscope
Split cells into 384-well plates 
(10,000 cells/50 ml medium/well)
Cultured in 0.1% serum
Experimental steps Notes
Culture HeLa cells on 100 mm dishes
in 10% serum
80% confluent
Add IGF (final concentration 5ng/ml) and 
insulin (final concentration 100ng/ml) to 
induce PH-EGFP membrane translocation
Compound transfer 
(100 nl/ well about 65,000 compounds) 
Fixation with 3% paraformaldehyde 
Wash cells with PBS/0.05% Triton X-100 and 
fill wells with PBS
12-16 hr
30 min
30 min
Stable cell line expressing PH-GFP
15 min
Matrix WellMate Microplate Dispenser
Identification of compounds blocking PH-EGFP 
plasma membrane translocation
Seiko pin-transfer robot
Figure S3. The flowchart of the cell-based high throughput screening for inhibitors of Akt plasma membrane 
translocation.
Matrix WellMate Microplate Dispenser 
Matrix WellMate Microplate Dispenser
Matrix WellMate Microplate Dispenser
Image analysis by MetaMorphTotal Akt
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Figure S10. Kinetics of Akt phosphorylation by SC79.  Serum-starved  cells (overnight) or cells 
grown in serum-containing medium (1% FBS) were treated with SC79 (4mg/ml) for indicated time. 
Total and phosphorylated Akt were detected by Western blot using anti-Akt and anti-Phospho-Akt 
(Ser473) antibodies, respectively. Bisindolylmaleimide IX 
(RO-31-8220) 
Bisindolylmaleimide I 
(GF109203X) 
HA14-1
Figure S11.  HA14-1, a structural analog of SC79, increases phosphorylation of both endogenous and mutant Akt 
(K14R) and enhances Akt signaling.  In contrast, BIM-IX and BIM-I, two kinase inhibitors of PKC, enhance 
phosphorylation of endogenous Akt but inhibit its kinase activity.  Both PKC and Akt belong to AGC family kinases with 
a similar kinase domain.  HeLa or HEK-Akt (K14R) cells were treated with the indicated amounts of chemicals for 30 
minutes.  The levels of phosphorylation of Akt and RPS6 (riobosomal protein S6), a target of AGC family kinase, were 
analyzed by Western blot.
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K26, R28, Y39 
Figure S12. Alignment of PH domains of Akt and Tec family tyrosine kinase (Itk and Btk).  
The critical residues for PtdIns(3,4,5)P3 binding were indicated by arrows.  7
9
S
C
7
9
12 hr in DMEM
before treatment
7
9
S
C
7
9
12 hr in DMEM
before treatment A
HEK293 NIH3T3
pAkt
N
o
 
S
C
7
F
r
e
s
h
 
S
3
7
 
o
C
0
 
o
C
before treatment
N
o
 
S
C
7
F
r
e
s
h
 
S
3
7
 
o
C
0
 
o
C
before treatment A
pAkt
 
h
r
)
d
a
y
) Akt
Mouse retina  after 
intraocular injection 
pAkt
pFoxo 1/3
D
M
S
O
I
n
s
u
l
i
n
 
(
1
S
C
7
9
 
(
3
 
d
B
C LY + SC79  wash drug 
 serum free medium  pAkt
Akt
- +       - +      - +    SC79
pAkt
B
0.5 hr         1 hr         2 hr
pFoxo 1/3
(longer exp.)
Akt
pFoxo 1/3
Figure S13. A sustained Akt activity after removal of SC79.  (A) Serum-deprived  HEK293 or NIH3T3 cells were treated 
with fresh SC79 (4 mg/ml) or SC79 pre-incubated in aqueous medium for 12 hr at 37oC or on ice.  The levels of pAkt and 
pFoxo were analyzed after 30 min-drug treatment.  (B)  HeLa cells were treated with LY294002 (40 M) and SC79 (4g/ml) 
for 30 min After removal of drug cells were left in serum free medium and the levels of pAkt and pFoxo were analyzed in for 30 min.  After removal of drug, cells were left in serum free medium and the levels of pAkt and pFoxo were analyzed in 
time course.  (C) SC79 (100ng) was intravitreally injected into mouse eyes and the level of pAkt and pFoxo was analyzed in 
the retina  on day 3.  The retina from 1 hour after  insulin (100 ng) injection  serves as a positive control for Akt activation. g
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Figure S14.  SC79 treatment does not alter the body weight and blood sugar level in experimental animals. SC79 was applied 
intravenously via tail vein injection at a concentration of 0.4 mg/g body weight.  The body weight and blood sugar levels were 
measured at each indicated time points. 